RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SinoMab BioScience - Stock

SinoMab BioScience Revenue 2024

SinoMab BioScience Revenue

1.37 M CNY

Ticker

3681.HK

ISIN

HK0000544194

In 2024, SinoMab BioScience's sales reached 1.37 M CNY, a 0% difference from the 0 CNY sales recorded in the previous year.

The SinoMab BioScience Revenue history

YEARREVENUE (undefined CNY)GROSS MARGIN (%)
20231.3730,92
2022--
202125.911,63
2020--
2019--
2018--
2017--

SinoMab BioScience Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SinoMab BioScience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SinoMab BioScience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SinoMab BioScience’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SinoMab BioScience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SinoMab BioScience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SinoMab BioScience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SinoMab BioScience’s growth potential.

SinoMab BioScience Revenue, EBIT and net profit per share

DateSinoMab BioScience RevenueSinoMab BioScience EBITSinoMab BioScience Net Income
20231.37 M CNY-228.97 M CNY-243.11 M CNY
20220 CNY-258.91 M CNY-284.16 M CNY
202125.91 M CNY-306.04 M CNY-288.19 M CNY
20200 CNY-162.76 M CNY-122.6 M CNY
20190 CNY-275.96 M CNY-276.28 M CNY
20180 CNY-55.42 M CNY-83.61 M CNY
20170 CNY-39.61 M CNY-47.97 M CNY

SinoMab BioScience stock margins

The SinoMab BioScience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SinoMab BioScience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SinoMab BioScience.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SinoMab BioScience's sales revenue. A higher gross margin percentage indicates that the SinoMab BioScience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SinoMab BioScience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SinoMab BioScience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SinoMab BioScience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SinoMab BioScience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SinoMab BioScience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SinoMab BioScience Margin History

SinoMab BioScience Gross marginSinoMab BioScience Profit marginSinoMab BioScience EBIT marginSinoMab BioScience Profit margin
202330.92 %-16,774.51 %-17,810.33 %
202230.92 %0 %0 %
202130.92 %-1,181.01 %-1,112.16 %
202030.92 %0 %0 %
201930.92 %0 %0 %
201830.92 %0 %0 %
201730.92 %0 %0 %

SinoMab BioScience Aktienanalyse

What does SinoMab BioScience do?

SinoMab BioScience Ltd is a Chinese biotechnology company specializing in the research, development, and commercial production of innovative biopharmaceutical products. The company was founded in 2001 and is based in Hong Kong. The company's business model focuses on the development of antibody-based therapies for the treatment of cancer and inflammatory diseases. SinoMab BioScience Ltd collaborates closely with leading biopharmaceutical companies, academic institutions, and research facilities worldwide to develop therapeutics that have the potential to improve patients' lives. The company operates in various sectors, including research and development, production, and distribution of biopharmaceutical products. SinoMab also has its own research and development department dedicated to the discovery and development of antibodies. The company aims to build a pipeline of innovative products that address a wide range of medical needs. Currently, SinoMab BioScience Ltd has a range of product candidates in clinical development targeting the treatment of cancer and inflammatory diseases. One of the key products is the antibody preparation SMM-114, used for the treatment of patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma and represents one of the most common cancers in adults. SMM-114 actively inhibits the proliferation of tumor cells by blocking the protein CXCR4, which is expressed on the surface of cancer cells. Another important product candidate of the company is SMAB022, a monoclonal antibody for the treatment of patients with cutaneous squamous cell carcinoma. This product binds to the Epidermal Growth Factor Receptor (EGFR) protein on the surface of cancer cells and inhibits their proliferation. SinoMab BioScience Ltd also has a manufacturing and distribution department for biopharmaceutical products. The company has a GMP-compliant production facility and offers services such as process development, production and purification procedures, stabilization, and formulation of biopharmaceuticals. In addition, SinoMab BioScience Ltd has developed its own in vitro diagnostic (IVD) test for the detection of human papillomavirus (HPV). This disease is one of the most common sexually transmitted infections and is a serious health problem. The HPV IVD is an innovative test system that enables rapid, accurate, and reliable identification of HPV infections. Research and development is highly valued by the company, and it has established its own R&D department consisting of experienced scientists and engineers. This department focuses on the discovery and development of novel biopharmaceutical products and collaborates closely with academic institutions and research facilities. Furthermore, SinoMab BioScience Ltd has formed partnerships with other leading biopharmaceutical companies to collaborate in exploring and harnessing the potential of antibodies for the treatment of diseases. In conclusion, SinoMab BioScience Ltd is an innovative biotechnology company specializing in the development of novel biopharmaceutical therapies for the treatment of cancer and inflammatory diseases. The company has a strong research and development expertise and has built a pipeline of product candidates with the potential to improve patients' lives. With its wide range of products and services in the manufacturing and distribution of biopharmaceuticals, SinoMab BioScience Ltd has established a strong position in the market. SinoMab BioScience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding SinoMab BioScience's Sales Figures

The sales figures of SinoMab BioScience originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing SinoMab BioScience’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize SinoMab BioScience's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in SinoMab BioScience’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about SinoMab BioScience stock

How much revenue did SinoMab BioScience generate this year?

SinoMab BioScience has achieved a revenue of 1.37 M CNY this year.

How much was the turnover of the company SinoMab BioScience compared to the previous year?

The revenue of SinoMab BioScience has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of SinoMab BioScience?

The revenue of SinoMab BioScience is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of SinoMab BioScience measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of SinoMab BioScience so important for investors?

The revenue of SinoMab BioScience is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does SinoMab BioScience pay?

Over the past 12 months, SinoMab BioScience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SinoMab BioScience is expected to pay a dividend of 0 CNY.

What is the dividend yield of SinoMab BioScience?

The current dividend yield of SinoMab BioScience is .

When does SinoMab BioScience pay dividends?

SinoMab BioScience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SinoMab BioScience?

SinoMab BioScience paid dividends every year for the past 0 years.

What is the dividend of SinoMab BioScience?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is SinoMab BioScience located?

SinoMab BioScience is assigned to the 'Health' sector.

Wann musste ich die Aktien von SinoMab BioScience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SinoMab BioScience from 7/6/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 7/6/2024.

When did SinoMab BioScience pay the last dividend?

The last dividend was paid out on 7/6/2024.

What was the dividend of SinoMab BioScience in the year 2023?

In the year 2023, SinoMab BioScience distributed 0 CNY as dividends.

In which currency does SinoMab BioScience pay out the dividend?

The dividends of SinoMab BioScience are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SinoMab BioScience

Our stock analysis for SinoMab BioScience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SinoMab BioScience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.